03-06-2024
With most (?) of the R&D of TCAT done, one would hope there would be only two outcomes:
. TCAT success i.e. some decent level of profitability, sufficient to justify historic and future costs. A big win from here (20p+).
or
. TCAT failure i.e. fails to gain traction and continues to be a cash burner. You'd hope they'd slim down costs in that case, so that the "rights" part of the company gets a reasonable valuation (operative NAV per Ordinary Share of 18p, don't forget, which doesn't look wild when you look at revenues and takeover valuation at SONG). A win from here (15p+).
So could be a case of win or win big. That caused me to buy, hopefully at the lows.
It's not, of course, ever that straightforward. The temptation to carry on with TCAT development, even after gaining traction looks unlikely will be high.
29-04-2024
Nothing to see here - yet.
At least I suppose the implied valuation of SONG from the takeover offers, gives the OMIP NAV some backup.
Meanwhile we await the culmination of the TCAT cunning plan and hope its not a Baldrick moment.